# Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

> **NCT00084656** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 77 (actual)

## Conditions studied

- Intraocular Melanoma
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** ipilimumab
- **BIOLOGICAL:** Tyrosinase/gp100/MART-1 Peptides

## Key facts

- **NCT ID:** NCT00084656
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05-31
- **Primary completion:** 2009-10-31
- **Final completion:** 2009-10-31
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2022-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084656, "Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00084656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*